218 related articles for article (PubMed ID: 11208038)
41. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.
Rippe B; Simonsen O; Heimbürger O; Christensson A; Haraldsson B; Stelin G; Weiss L; Nielsen FD; Bro S; Friedberg M; Wieslander A
Kidney Int; 2001 Jan; 59(1):348-57. PubMed ID: 11135090
[TBL] [Abstract][Full Text] [Related]
42. [Peritonitis during continuous ambulatory peritoneal dialysis. Lavage treatment or not? A prospective study].
De Groc F; Rottembourg J; Jacq D; Jarlier V; N'Guyen J; Legrain M
Nephrologie; 1983; 4(1):24-7. PubMed ID: 6843764
[TBL] [Abstract][Full Text] [Related]
43. Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report.
Kamijo Y; Iida H; Saito K; Furutera R; Ishibashi Y
Perit Dial Int; 2013; 33(6):712-4. PubMed ID: 24335133
[No Abstract] [Full Text] [Related]
44. APD schedules and clinical results.
Durand PY
Contrib Nephrol; 2003; (140):272-7. PubMed ID: 12800369
[No Abstract] [Full Text] [Related]
45. Culture-negative peritonitis caused by splenic infarction in a continuous ambulatory peritoneal dialysis patient.
Yoon HE; Kim I; Kim YW; Chung HW; Shin SJ
Intern Med; 2012; 51(15):1997-2000. PubMed ID: 22864125
[TBL] [Abstract][Full Text] [Related]
46. Fungal peritonitis in patients on peritoneal dialysis: incidence, clinical features and prognosis.
Johnson RJ; Ramsey PG; Gallagher N; Ahmad S
Am J Nephrol; 1985; 5(3):169-75. PubMed ID: 4014323
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness and efficiency of methods of dialysis therapy for end-stage renal disease: systematic reviews.
MacLeod A; Grant A; Donaldson C; Khan I; Campbell M; Daly C; Lawrence P; Wallace S; Vale L; Cody J; Fitzhugh K; Montague G; Ritchie C
Health Technol Assess; 1998; 2(5):1-166. PubMed ID: 9621129
[No Abstract] [Full Text] [Related]
48. Peritoneal abnormalities during infectious episodes of continuous ambulatory peritoneal dialysis.
Rubin J; Ray R; Barnes T; Bower J
Nephron; 1981; 29(3-4):124-7. PubMed ID: 7329486
[TBL] [Abstract][Full Text] [Related]
49. Continuous ambulatory peritoneal dialysis. Technique of catheter insertion and management of associated surgical complications.
Olcott C; Feldman CA; Coplon NS; Oppenheimer ML; Mehigan JT
Am J Surg; 1983 Jul; 146(1):98-102. PubMed ID: 6869687
[TBL] [Abstract][Full Text] [Related]
50. Association between nitric oxide and oxidative stress in continuous ambulatory peritoneal dialysis patients with peritonitis.
Duranay M; Yilmaz FM; Yilmaz G; Akay H; Parpucu H; Yücel D
Scand J Clin Lab Invest; 2007; 67(6):654-60. PubMed ID: 17852815
[TBL] [Abstract][Full Text] [Related]
51. Peritoneal nitric oxide is a marker of peritonitis in patients on continuous ambulatory peritoneal dialysis.
Yang CW; Hwang TL; Wu CH; Lai PC; Huang JY; Yu CC; Shyr MH; Huang CC
Nephrol Dial Transplant; 1996 Dec; 11(12):2466-71. PubMed ID: 9017624
[TBL] [Abstract][Full Text] [Related]
52. ["Abdominal catastrophe" in peritoneal dialysis].
Olszowska A; Dziekiewicz M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):183-6. PubMed ID: 15603334
[TBL] [Abstract][Full Text] [Related]
53. Persistent transforming growth factor-beta 1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence.
Lin CY; Chen WP; Yang LY; Chen A; Huang TP
Am J Nephrol; 1998; 18(6):513-9. PubMed ID: 9845827
[TBL] [Abstract][Full Text] [Related]
54. Cellular response to peritonitis among peritoneal dialysis patients.
Flanigan MJ; Freeman RM; Lim VS
Am J Kidney Dis; 1985 Dec; 6(6):420-4. PubMed ID: 4073021
[TBL] [Abstract][Full Text] [Related]
55. Peritonitis caused by Roseomonas in a patient undergoing automated peritoneal dialysis: case report and literature review.
Tsai SF; Chen CH; Shu KH; Wu MJ
Intern Med; 2012; 51(13):1721-4. PubMed ID: 22790133
[TBL] [Abstract][Full Text] [Related]
56. Low or high calcium dialysate solutions in peritoneal dialysis?
Weinreich T
Kidney Int Suppl; 1996 Nov; 56():S92-6. PubMed ID: 8914061
[No Abstract] [Full Text] [Related]
57. A randomized controlled trial of alanyl-glutamine supplementation in peritoneal dialysis fluid to assess impact on biomarkers of peritoneal health.
Vychytil A; Herzog R; Probst P; Ribitsch W; Lhotta K; Machold-Fabrizii V; Wiesholzer M; Kaufmann M; Salmhofer H; Windpessl M; Rosenkranz AR; Oberbauer R; König F; Kratochwill K; Aufricht C
Kidney Int; 2018 Dec; 94(6):1227-1237. PubMed ID: 30360960
[TBL] [Abstract][Full Text] [Related]
58. Growth of coagulase negative staphylococci in peritoneal dialysate fluid. Effect of calcium concentration.
Morton AR; Evans G; Shannon A; Zoutman D
ASAIO J; 1994; 40(3):M431-4. PubMed ID: 8555552
[TBL] [Abstract][Full Text] [Related]
59. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
60. Peritonitis during continuous ambulatory peritoneal dialysis: improving patient defense by type of buffer of dialysate?
Binswanger U; Keusch G; Bammatter F; Heule H; Kiss D
Nephron; 1981; 28(6):300-2. PubMed ID: 7312085
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
